$AQST
Aquestive Therapeutics, Inc. Stock $aqst

$aqst Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024021118 Filed on May 07, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$20.10M	$12.05M
YoY Change	51.79%	8.25%
Cost Of Revenue	$4.526M	$4.389M
YoY Change	-31.6%	-7.35%
Gross Profit	$15.57M	$7.664M
YoY Change	135.1%	19.81%
Gross Profit Margin	77.48%	63.59%
Selling, General & Admin	$11.36M	$10.69M
YoY Change	54.29%	43.38%
% of Gross Profit	72.92%	139.47%
Research & Development	$4.162M	$5.932M
YoY Change	19.84%	67.24%
% of Gross Profit	26.73%	77.4%
Depreciation & Amortization	$165.0K	$168.0K
YoY Change	-34.0%	-41.26%
% of Gross Profit	1.06%	2.19%
Operating Expenses	$15.52M	$16.62M
YoY Change	43.25%	51.07%
Operating Profit	$55.00K	-$8.957M
YoY Change	-101.31%	94.51%
Interest Expense	$2.779M	$2.784M
YoY Change	102.4%	94.01%
% of Operating Profit	5052.73%
Other Income/Expense, Net	-$1.416M	-$1.416M
YoY Change
Pretax Income	-$2.745M	-$12.83M
YoY Change	-50.16%	-259.0%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.745M	-$12.83M
YoY Change	-52.61%	-259.0%
Net Earnings / Revenue	-13.66%	-106.43%
Basic Earnings Per Share	-$0.03	-$0.17
Diluted Earnings Per Share	-$0.03	-$0.17
COMMON SHARES
Basic Shares Outstanding	91.04M shares	73.30M shares
Diluted Shares Outstanding	90.91M shares	73.61M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$89.87M	$95.20M
YoY Change	300.56%	254.14%
Cash & Equivalents	$89.87M	$95.20M
Short-Term Investments
Other Short-Term Assets	$1.177M	$2.121M
YoY Change	-9.53%	-7.46%
Inventory	$6.966M	$7.734M
Prepaid Expenses
Receivables	$5.998M	$8.324M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$104.0M	$113.4M
YoY Change	161.41%	159.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.921M	$4.046M
YoY Change	-14.8%	6.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.238M	$5.417M
YoY Change	-22.51%	-16.47%
Total Long-Term Assets	$13.59M	$16.14M
YoY Change	-20.99%	-8.16%
TOTAL ASSETS
Total Short-Term Assets	$104.0M	$113.4M
Total Long-Term Assets	$13.59M	$16.14M
Total Assets	$117.6M	$129.5M
YoY Change	106.35%	111.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.696M	$10.52M
YoY Change	-46.71%	-15.41%
Accrued Expenses	$5.674M	$4.637M
YoY Change	33.1%	2.86%
Deferred Revenue	$1.046M	$1.551M
YoY Change	-73.8%	-67.45%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$24.00K	$23.00K
YoY Change	-99.87%	-99.87%
Total Short-Term Liabilities	$13.90M	$18.06M
YoY Change	-64.05%	-55.28%
LONG-TERM LIABILITIES
Long-Term Debt	$30.01M	$28.76M
YoY Change	44.25%	14.14%
Other Long-Term Liabilities	$2.027M	$2.021M
YoY Change	1.05%	-1.85%
Total Long-Term Liabilities	$2.027M	$2.021M
YoY Change	1.05%	-1.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.90M	$18.06M
Total Long-Term Liabilities	$2.027M	$2.021M
Total Liabilities	$153.1M	$165.8M
YoY Change	-6.45%	-2.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$334.7M	-$331.9M
YoY Change	8.33%	9.49%
Common Stock	$91.00K	$90.00K
YoY Change	46.77%	60.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$35.48M	-$36.30M
YoY Change
Total Liabilities & Shareholders Equity	$117.6M	$129.5M
YoY Change	106.35%	111.35%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$2.745M	-$12.83M
YoY Change	-52.61%	-259.0%
Depreciation, Depletion And Amortization	$165.0K	$168.0K
YoY Change	-34.0%	-41.26%
Cash From Operating Activities	-$7.006M	-$10.38M
YoY Change	-11.39%	-217.79%
INVESTING ACTIVITIES
Capital Expenditures	$35.00K	$29.00K
YoY Change	-95.76%	1350.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$35.00K	-$29.00K
YoY Change	-95.76%	1350.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.711M	$81.74M
YoY Change	-60.09%	-988.01%
NET CHANGE
Cash From Operating Activities	-7.006M	-$10.38M
Cash From Investing Activities	-35.00K	-$29.00K
Cash From Financing Activities	1.711M	$81.74M
Net Change In Cash	-5.330M	$71.33M
YoY Change	19.88%	-18342.46%
FREE CASH FLOW
Cash From Operating Activities	-$7.006M	-$10.38M
Capital Expenditures	$35.00K	$29.00K
Free Cash Flow	-$7.041M	-$10.41M
YoY Change	-19.37%	-218.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90478731	shares
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4737000	usd
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90478731	shares
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4389000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5932000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3547000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10689000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7455000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	21010000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	15739000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8957000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4605000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	2784000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1435000	usd
CY2024Q1	us-gaap	Royalty Expense RoyaltyExpense	1358000	usd
CY2023Q1	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2024Q1	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	58000	usd
CY2023Q1	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	52000	usd
CY2024Q1	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	329000	usd
CY2023Q1	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	14513000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-353000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12828000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8068000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	539000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-12828000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	8068000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12828000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	8068000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73614710	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55631947	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73614710	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73792886	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-106487000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1580000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-893000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	231400	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	539000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	539000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-12828000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-36301000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-118554000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	993000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	77000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	344000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-8000	usd
CY2023Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	1000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	8068000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-109235000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-12828000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	8068000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	207000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	325000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1580000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	344000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2673000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	56000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-32000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	260000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-147000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	2217000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	965000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1201000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	253000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	195000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1284000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2494000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1873000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3472000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-388000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4874000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10384000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8816000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2024Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	5000	usd
CY2023Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	9086000	usd
CY2024Q1	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
CY2023Q1	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1027000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	893000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	8000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	81741000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9205000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	71328000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-391000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23872000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27273000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95200000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26882000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1003000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1466000	usd
CY2024Q1	aqst	Costs Associated With Public Offering In Accounts Payable CostsAssociatedWithPublicOfferingInAccountsPayable	313000	usd
CY2023Q1	aqst	Costs Associated With Public Offering In Accounts Payable CostsAssociatedWithPublicOfferingInAccountsPayable	0	usd
CY2024Q1	aqst	Revenue From Contract With Customer Number Of Commercialized Products RevenueFromContractWithCustomerNumberOfCommercializedProducts	5	product
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95200000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-331905000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	700000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	1662000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	33508000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	33896000	usd
CY2024Q1	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	701000	usd
CY2023Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	715000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12053000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11134000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12053000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11134000	usd
CY2024Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	6703000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	5570000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1635000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2915000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2024Q1	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	8324000	usd
CY2023Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	8471000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	26000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	3043000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2118000	usd
CY2024Q1	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	2874000	usd
CY2023Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	3028000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1817000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1623000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	7734000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6769000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47092000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47063000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	43046000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	42884000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4046000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4179000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	168000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	286000	usd
CY2024Q1	aqst	Number Of Operating Leases NumberOfOperatingLeases	3	lease
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	444000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	115000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	418000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	108000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	926000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1266000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1300000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1328000	usd
CY2024Q1	aqst	Lessee Operating Lease Liability To Be Paid Year Four And Thereafter LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter	4990000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9810000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4112000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5698000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3128000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3089000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1239000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1278000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	39000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	39000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	118000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	157000	usd
CY2024Q1	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	4000000	usd
CY2023Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	4000000	usd
CY2024Q1	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1417000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1438000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5417000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5438000	usd
CY2024Q1	aqst	Number Of Guaranteed Royalty Payments NumberOfGuaranteedRoyaltyPayments	8	royalty_payment
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1731000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4202000	usd
CY2024Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	433000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	337000	usd
CY2024Q1	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	640000	usd
CY2023Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	645000	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	1536000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1013000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	297000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	300000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4637000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6497000	usd
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2019Q3	aqst	Net Proceeds From Issuance Of Initial Notes Warrants And First Offer Rights NetProceedsFromIssuanceOfInitialNotesWarrantsAndFirstOfferRights	66082000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9540000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	14535000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	20925000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	45000000	usd
CY2024Q1	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
CY2023Q1	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
CY2022Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	5874000	usd
CY2024Q1	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
CY2023Q1	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
CY2023Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	64490000	usd
CY2022Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	65259000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	58000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	220000	usd
CY2024Q1	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	910000	usd
CY2023Q4	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	922000	usd
CY2024Q1	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	64536000	usd
CY2023Q1	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	64490000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-12828000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	8068000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73614710	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55631947	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	10564429	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73614710	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73792886	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1580000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	344000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1580000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	344000	usd
CY2024Q1	aqst	Inducement Equity Common Stock Options Outstanding Shares InducementEquityCommonStockOptionsOutstandingShares	0	shares
CY2023Q4	us-gaap	Share Price SharePrice	4.26
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12828000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	8068000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-021118-index-headers.html	Edgar Link	pending
0001628280-24-021118-index.html	Edgar Link	pending
0001628280-24-021118.txt	Edgar Link	pending
0001628280-24-021118-xbrl.zip	Edgar Link	pending
aqst-20240331.htm	Edgar Link	pending
aqst-20240331.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
q12024ex311.htm	Edgar Link	pending
q12024ex312.htm	Edgar Link	pending
q12024ex321.htm	Edgar Link	pending
q12024ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
aqst-20240331_cal.xml	Edgar Link	unprocessable
aqst-20240331_def.xml	Edgar Link	unprocessable
aqst-20240331_lab.xml	Edgar Link	unprocessable
aqst-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
aqst-20240331_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AQST
Aquestive Therapeutics, Inc. Stock $aqst

2024 Q2 Form 10-Q Financial Statement

#000162828024021118 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST Aquestive Therapeutics, Inc. Stock $aqst

2024 Q2 Form 10-Q Financial Statement

#000162828024021118 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST
Aquestive Therapeutics, Inc. Stock $aqst